Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
December 17th, 2024
News
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
APDN to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
December 16th, 2024
Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
October 30th, 2024
Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
October 15th, 2024
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
September 18th, 2024
Applied DNA Launches Mpox Clade I and Clade II Testing Service
September 17th, 2024
Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
September 17th, 2024
Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
September 4th, 2024
Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
August 23rd, 2024